Neuralink’s private valuation has been shaped by robust secondary market trading in 2026, with implied levels ranging from $29 billion to as high as $60 billion on platforms tracking transactions, compared with the $9 billion post-money valuation from its June 2025 Series E round. Recent clinical progress, including late-October demonstrations of thought-to-speech decoding in ALS patients from the VOICE trial, reinforced trader sentiment around technological milestones and potential regulatory pathways. Nasdaq Private Market daily prices through October served as the primary reference for assessing whether any threshold was met by the 31st, with no IPO or public listing altering the data set. Market-implied odds in related contracts reflect this mix of secondary pricing momentum and ongoing uncertainty around clinical and funding developments.